Oral Treatment with CuII(atsm) Increases Mutant SOD1 In Vivo but Protects Motor Neurons and Improves the Phenotype of a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis by Roberts, Blaine R. et al.
Neurobiology of Disease
Oral Treatment with CuII(atsm) Increases Mutant SOD1 In
Vivo but Protects Motor Neurons and Improves the Phenotype
of a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis
Blaine R. Roberts,1* Nastasia K. H. Lim,2* Erin J. McAllum,2* Paul S. Donnelly,3,4 Dominic J. Hare,1,6 Philip A. Doble,6
Bradley J. Turner,1 Katherine A. Price,2 Sin Chun Lim,3,4 Brett M. Paterson,3,4 James L. Hickey,3,4 Timothy W. Rhoads,7,8
Jared R. Williams,7,8 Katja M. Kanninen,2 Lin W. Hung,1,4 Jeffrey R. Liddell,2 Alexandra Grubman,2 Jean-Francois Monty,10
Roxana M. Llanos,10 David R. Kramer,11 Julian F. B. Mercer,10 Ashley I. Bush,1 X Colin L. Masters,1 James A. Duce,1,12
Qiao-Xin Li,1 Joseph S. Beckman,7,8,9 Kevin J. Barnham,1,4,5 Anthony R. White,1,2 and Peter J. Crouch1,2
1Florey Institute of Neuroscience and Mental Health, 2Department of Pathology, 3School of Chemistry, 4Bio21 Institute of Biotechnology and Molecular
Biology, and 5Department of Pharmacology, The University of Melbourne, Parkville, 3010 Victoria, Australia, 6Elemental Bio-imaging Facility, and
Department of Chemistry and Forensic Science, University of Technology Sydney, 2007 Broadway, New South Wales, Australia, 7Department of
Biochemistry and Biophysics, 8Linus Pauling Institute, and 9Environmental Health Sciences Centre, Oregon State University, Corvallis, Oregon 97331,
10Centre for Cellular and Molecular Biology, School of Life and Environmental Sciences, Deakin University, Burwood, 3125 Victoria, Australia, 11ANU
Medical School, ANU College of Medicine, Biology and the Environment, The Australian National University, 0200 Canberra, Australian Capital Territory,
Australia, and 12School of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, United Kingdom
Mutations in the metallo-protein Cu/Zn-superoxide dismutase (SOD1) cause amyotrophic lateral sclerosis (ALS) in humans and an
expression level-dependent phenotype in transgenic rodents. We show that oral treatment with the therapeutic agent diacetyl-bis(4-
methylthiosemicarbazonato)copper II [Cu II(atsm)] increased the concentration of mutant SOD1 (SOD1G37R) in ALS model mice, but
paradoxically improved locomotor function and survival of the mice. To determine why the mice with increased levels of mutant SOD1
had an improved phenotype, we analyzed tissues by mass spectrometry. These analyses revealed most SOD1 in the spinal cord tissue of
the SOD1G37R mice was Cu deficient. Treating with Cu II(atsm) decreased the pool of Cu-deficient SOD1 and increased the pool of fully
metallated (holo) SOD1. Tracking isotopically enriched 65Cu II(atsm) confirmed the increase in holo-SOD1 involved transfer of Cu from
Cu II(atsm) to SOD1, suggesting the improved locomotor function and survival of the Cu II(atsm)-treated SOD1G37R mice involved, at
least in part, the ability of the compound to improve the Cu content of the mutant SOD1. This was supported by improved survival of
SOD1G37R mice that expressed the human gene for the Cu uptake protein CTR1. Improving the metal content of mutant SOD1 in vivo with
Cu II(atsm) did not decrease levels of misfolded SOD1. These outcomes indicate the metal content of SOD1 may be a greater determinant
of the toxicity of the protein in mutant SOD1-associated forms of ALS than the mutations themselves. Improving the metal content of
SOD1 therefore represents a valid therapeutic strategy for treating ALS caused by SOD1.
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset disease
in which motor neurons in the spinal cord and brain progres-
sively deteriorate and die. Initial clinical symptoms of ALS are
relatively mild, but inevitably progress to paralysis and premature
death as the extent of motor neuron failure increases. Riluzole
(trade name Rilutek) is the only approved treatment for ALS, but
its therapeutic effects are minimal. Treatment with riluzole pro-
vides an approximate 3 month increase in patient survival and
has no effect on the deterioration of muscle strength (BensimonReceived Sept. 30, 2013; revised April 30, 2014; accepted May 2, 2014.
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et al., 1994; Lacomblez et al., 1996; Miller et al., 1996). The devel-
opment of new treatment strategies for ALS is needed.
Approximately 90% of ALS cases are sporadic, and 10% are
familial. Several genes are associated with the development of
ALS, including TARDBP (Sreedharan et al., 2008) and C9ORF72
(DeJesus-Hernandez et al., 2011; Renton et al., 2011), but the
gene for the ubiquitous antioxidant enzyme Cu/Zn-superoxide
dismutase (SOD1) is the most widely studied to date and has
provided the basis for the development of the most robust animal
models of ALS. Over 100 different SOD1 mutations account for
20% of familial ALS cases (Rosen et al., 1993), and SOD1 mu-
tations are also present in sporadic forms of the disease (Ander-
sen et al., 2003). Nonmutated, wild-type SOD1 is aberrantly
metabolized in sporadic cases of ALS (Bosco et al., 2010), and
overexpression of wild-type SOD1 causes an ALS-like phenotype
in mice that is comparable to the phenotype of ALS model mice
caused by the expression of mutant SOD1 (Graffmo et al., 2013).
Thus, the pathogenic role of SOD1 in ALS appears to extend
beyond familial cases that involve SOD1 mutations.
Although oxidative damage is conspicuous in disease-affected
tissues (Niebrój-Dobosz et al., 2004), SOD1 mutations do not
cause ALS by a loss of antioxidant function (Bruijn et al., 1998).
Motor neuron death in SOD1-associated forms of ALS therefore
represents the consequences of a toxic gain of function in the
mutant protein. Underscoring this, transgenic mice overexpress-
ing mutant SOD1 develop an ALS-like phenotype that is propor-
tional to the expression level of the mutant SOD1. Higher levels
of mutant SOD1 cause earlier disease onset, more severe disease
symptoms, and more rapid disease progression (Gurney et al.,
1994; Wong et al., 1995; Henriques et al., 2010). However, de-
spite the clear link between motor neuron death and disease
symptoms in SOD1-associated forms of ALS, the fundamental
basis of SOD1 toxicity in ALS is not fully understood. To
address this, the present study examined spinal cord tissue col-
lected from ALS model mice (SOD1G37R; Wong et al., 1995) that
had been treated with the therapeutic agent diacetyl-bis(4-
methylthiosemicarbazonato)copper II [Cu II(atsm)]. Given that
the ALS-like phenotype of these mice is driven by expression of
the mutant SOD1, the aim of the study was to investigate the
relationship between therapeutic activity of Cu II(atsm) and its
effects on SOD1.
Materials and Methods
SOD1G37R mice. SOD1G37R mice (Wong et al., 1995) were used in this
study. The effects of Cu II(atsm) have been investigated previously in a
G93A mouse model of ALS (Soon et al., 2011). SOD1G37R mice pur-
chased from The Jackson Laboratory, and a colony was maintained by
breeding SOD1G37R-positive mice with nontransgenic C57BL/6 mice.
Mice were housed in standard boxes (two to five mice per box) with
access to food and water ad libitum. Bedding for the boxes contained only
saw dust and shredded paper, with no other environmental enrichment.
Mice were maintained under a 12 h light/dark cycle. Mice were geno-
typed using tail snips obtained from the mice at the age of weaning (3
weeks of age). The genotyping of all mice was determined using the
commercial Extract-N-Amp Plant PCR Kit (Sigma), as per the manufac-
turer’s instructions to extract DNA from the sample tissue and to prepare
samples for PCR (primers and cycling steps were obtained from The
Jackson Laboratory website). The PCR product was run on a 1.7% aga-
rose gel at 100 V for 30 min and then imaged using the UVP BioDoc-It
System (Pathtech).
All treatment groups contained approximately equal numbers of male
and female mice. One cohort of mice was studied through to disease end
stage to obtain data on locomotor function. A second cohort of mice was
culled at 24 weeks of age to collect tissues for biochemical and histological
analyses. All mouse procedures were approved by the Animal Ethics
Committees of The University of Melbourne and the Mental Health
Research Institute and complied with guidelines from the Australian
National Health and Medical Research Council.
Treatment with CuII(atsm). Cu II(atsm) was synthesized as previously
described (Gingras et al., 1962; Blower et al., 2003), and a suspension of
the compound was prepared daily in standard suspension vehicle [SSV;
0.9% (w/v) NaCl, 0.5% (w/v) Na-carboxymethylcellulose (medium
viscosity), 0.5% (v/v) benzyl alcohol, and 0.4% (v/v) Tween-80]. Cu II-
(atsm) in SSV was administered daily to SOD1G37R mice or nontrans-
genic littermates by gavage, commencing at 40 d of age, at a dose of 30
mg/kg body weight/d. An equivalent volume of SSV was administered to
sham-treated mice. For some experiments, mice were treated with
65Cu II(atsm) synthesized as per the standard Cu II(atsm) except that the
initial Cu source was 65CuO (Trace Sciences International). In these
experiments, SOD1G37R mice were treated with 65Cu II(atsm), SSV, or
Cu II(atsm) by daily gavage for 2 weeks commencing when they were 12
weeks old. Mice in these experiments received Cu II(atsm)/ 65Cu II(atsm)
at 30 mg/kg body weight.
hCTR1xSOD1G37R mice. The human copper transporter 1 (hCTR1)
coding sequence was amplified from human fibroblast mRNA. The for-
ward primer was used to introduce a Flag epitope just upstream from the
start codon, and the reverse primer was located just after the stop codon.
The PCR product was cloned into pCMB336 (Ke et al., 2006). A 4.1 kb
PvuI/StuI fragment containing the CAG promoter, the hCTR1 insert,
and a polyA signal was purified and used at 2 ng/l for pronuclear mi-
croinjections in C57BL/6 females (Mouseworks, Monash University,
Melbourne, Victoria, Australia). hCTR1 mice were genotyped by PCR of
genomic DNA isolated from ear notches (Viagen Biotech). The detection
of the hCTR1 transgene and the endogenous mCtr1 gene (as a control for
the integrity of the extracted DNA) was performed with the following
primers:senseoligonucleotidehCTR1#1(5-TAAGTCACAAGTCAGCA
TTCGC), corresponding to the coding sequence of the hCTR1 transgene
and the antisense oligonucleotide SP6(2) from the vector (5-
GCTCTAGCATTTAGGTGACACTATAG); the sense oligonucleotide
mCtr1 #2 (5-GCCAAGAGACCTTTGCTCTG) and the antisense oligo-
nucleotide mCtr1 #3 (5-GCACCTTAATGTTGGGCTGT), correspond-
ing to the 3 untranslated region of the endogenous mCtr1 gene. C57BL/6
mice positive for the hCTR1 transgene were backcrossed for two gener-
ations, then bother/sister mating continued for a further seven genera-
tions. Double-transgenic hCTR1xSOD1G37R mice were created by
mating SOD1G37R hemizygotes with hCTR1 hemizygotes. Litters were
genotyped for all possible genetic variants via PCR, as described above.
hCTR1 expression was quantified using qRT-PCR methods that were
described previously (Kanninen et al., 2013) with all cDNA synthesis and
qRT-PCR reagents from Life Technologies. Briefly, RNA from nontrans-
genic and transgenic hCTR1 mouse spinal cord tissue (5 mg) was iso-
lated, and treated with DNase using the MagMAX-96 Total RNA
Isolation Kit. RNA concentrations were quantified using the Qubit 2.0
Fluorometer, then 200 ng of RNA was reverse transcribed using the High
Capacity cDNA Reverse Transcription Kit. Primers for hCTR1 were
GCTGGAAGAAGGCAGTGGTA and GGCCACGCCATAGAGTTTG,
and for mCtr1 they were TTCTTCAGGGTAGCTTCCGAGTA and
CAACCTAGCGCAGGGATCT. Each 10 l reaction mix consisted of 300
nM primers, 5 l 2 Power SYBR Green Master Mix, and 20 ng of cDNA
template. Duplicate reactions were performed using the LightCycler 480
(Roche) and the following conditions: 10 min at 95°C, followed by 45
cycles of 15 s at 95°C, and 60°C for 60 s. Cycle threshold (Ct) values were
calculated as the lowest cycle number producing an exponential increase
in PCR product amplification. Samples with Ct values 30 were ex-
cluded from all analyses. The Ct method was used to normalize hCTR1
gene expression in each sample to the expression of endogenous mCtr1.
To assess whether hCTR1 expression altered the expression of endoge-
nous mCtr1, the Ct method was used to normalize mCtr1 gene expres-
sion in each sample to the expression of endogenous mActb.
Locomotor function. Mice were tested for a locomotor function using
the rotarod assay. Mice were trained for 5 d before data were recorded for
analysis. During the data collection phase of the study, the mice were
tested on the rotarod twice a week. For SOD1G37R mice treated with
Cu II(atsm), the rotation speed of the rotarod was 25 rpm, and the time
8022 • J. Neurosci., June 4, 2014 • 34(23):8021– 8031 Roberts et al. • CuII(atsm) and Mutant SOD1 in ALS Mice
that each mouse could no longer stay on the rotarod (latency to fall) was
recorded up to a maximum of 180 s. For mice in the hCTR1xSOD1G37R
study, the rotation speed of the rotarod accelerated from 4 to 40 rpm over
180 s. Mice were placed on the rotarod twice during each testing period,
and only their maximum score recorded for analysis. Researchers per-
forming the rotarod assay were blinded to the treatments.
Mouse survival. SOD1G37R mice eventually develop limb paralysis
that prevents them from accessing food and water, and individual mice in
this study, regardless of treatment, were culled once they reached this
stage. This stage was identified as the point at which individual mice had
complete paralysis in at least one hindlimb and
were unable to right themselves within 15 s af-
ter being laid down on their side. All survival
data presented in this study therefore represent
the age at which the mice reached this disease
stage. Researchers who culled mice were
blinded to the treatments and mouse genotype.
Tissue collection. Mice allocated to collecting
tissues for biochemical analyses were killed
when 24 weeks old. These mice were killed by
intraperitoneal injection of PBS supplemented
with ketamine (20 mg/ml) and xylazine (4 mg/
ml), followed by transcardial perfusion with
PBS containing 0.25% phosphatase inhibitor
mixture, 1% protease inhibitor (Roche), and
20 U/ml heparin. After perfusion, spinal cords
and brains were removed. A small 5 mm sec-
tion of the lumbar region of the spinal cord was
removed and submersion fixed in 4% (v/v)
paraformaldehyde, and a similar lumbar sec-
tion was snap frozen on dry ice for subsequent
mass spectrometry analyses. The remaining
spinal cord material was snap frozen on dry ice
for subsequent protein extraction and addi-
tional biochemical analyses.
SDS-PAGE. Spinal cords were homogenized
using disposable polypropylene pestles for
Microfuge tubes (USA Scientific) in PBS
supplemented with protease and phosphatase
inhibitors (Sigma), then PBS-soluble and PBS-
insoluble fractions were collected by centrifu-
gation (16,000  g, for 30 min at 4°C). After
determining the protein content via the BCA
Assay (Thermo Scientific), samples were pre-
pared in a sample buffer [62.6 mM Tris, 5%
(v/v) glycerol, 2% (w/v) SDS, and 0.0025%
(w/v) bromophenol blue], then were loaded
onto 12% NuPAGE Novex Bis-Tris gels (Life
Technologies) and electrophoresed at 175 V
for 60 min in MES SDS running buffer (Life
Technologies). Resolved proteins were trans-
ferred to PVDF membranes, and Western blot-
ting was performed as described previously
(Donnelly et al., 2012). The primary antibodies
that were used were raised to detect human SOD1
(Abcam), mouse SOD1 (Abnova), and GAP43
(Novus Biologicals). Antibody immunoreactiv-
ity was detected using enhanced chemilumines-
cence (ECL Advance, GE Healthcare) and a
FujiFilm LAS-3000 imager. Chemilumines-
cence images were saved as TIFF files, and the
relative intensity of immunoreactivity was de-
termined using NIH ImageJ version 1.38x soft-
ware.
Native PAGE. PBS-soluble and PBS-
insoluble spinal cord extracts generated as de-
scribed above were prepared in native PAGE
sample buffer [100 mM Tris, 10% (v/v) glycerol,
0.0025% (w/v) bromophenol blue, pH 8.6], then
resolved on 12% tris-glycine gels (Life Technolo-
gies) at 125 V for 100 min in native tris-glycine running buffer (Life Tech-
nologies) before transferring to PVDF membranes as described above.
Membranes were probed using the primary antibodies A5C3, B8H10, and
C4F6 (MédiMabs). All three of these antibodies were generated to specifi-
cally detect misfolded forms of human SOD1 but not natively folded
wild-type SOD1, and data supporting this conformation-dependent immu-
noreactivity have been presented (Bosco et al., 2010; Gros-Louis et al., 2010).
Immunoreactivity for these three antibodies was detected and quantified as
described above.
Figure 1. Effects of Cu II(atsm) on locomotor function of SOD1G37R mice. A, Locomotor function of SOD1G37R mice measured as
latency to fall on the rotarod assay (n  10 sham-treated SOD1G37R mice, n  6 Cu II(atsm)-treated SOD1G37R mice). The dashed
line at 24 weeks represents an additional cohort of mice that was culled for all analyses shown in B–D and in Figures 2-5. The p
value shown represents the statistical significance of the treatment effect (two-way repeated-measures ANOVA). B, Number of
motor neurons present in the lumbar region of spinal cords from SOD1G37R mice and nontransgenic littermates. C, Abundance of oxida-
tively modified proteins determined using the OxyBlot assay in spinal cord tissue expressed relative to levels detected in sham-treated,
nontransgenic littermate controls. D, Representative histology images for GFAP (top row) and Iba-1 (bottom row) immunoreactivity in
spinal cord transverse sections. Asterisks in B and C represent the statistical significance of the data as follows: *p0.05, **p0.01. n
4 – 8 for all treatment groups for data in B–D. Error bars represent the SEM.
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Histology. Histology was performed based on methods previously de-
scribed (Li et al., 2006). Lumbar sections of mouse spinal cord were fixed
in 4% (w/v) paraformaldehyde in PBS, then were embedded in wax and
transverse 5 or 20 m sections were collected on glass slides. The 20 m
sections were stained for nucleic acid material using cresyl violet (700 M
in dH2O, pH 3.8, with 1% acetic acid), then -motor neurons in the
ventral horn were counted using light microscopy. Thirty-six sections
from spinal cord regions spanning 1800 m along the longitudinal
plane of the spinal cord were counted per mouse. The data presented in
Figure 1B represent the total number of -motor neurons counted per
mouse per ventral horn. To assess the levels of Iba-1 and GFAP, 5 m
sections were quenched with peroxide, blocked with 20% (v/v) serum,
then were incubated with primary antibody (1:1000) overnight at 4°C.
To assess the levels of human SOD1 and misfolded forms there of
proteinase-K-treated, 5 m sections were blocked with 20% (v/v) serum
then were incubated overnight at 4°C with primary antibodies to mis-
folded SOD1, as described above. Sections were developed using the
universal LSABHRP kit (Dako), as described by the manufacturer.
Protein oxidation. PBS-soluble tissue extracts, prepared as described
above, were analyzed for oxidatively modified proteins using the OxyBlot
Protein Oxidation Detection Kit (Millipore). Oxidatively modified pro-
teins were derivatized as per kit instructions then loaded onto 12% tris-
glycine gels (Life Technologies) before transfer to PVDF membranes as
described above. Membranes were probed for derivatized proteins using
kit antibodies, and oxidatively modified proteins were detected via
chemiluminescence as described above.
SOD activity assay. SOD activity gels were performed as previously
described (Soon et al., 2011). Briefly, soluble samples collected from
spinal cord tissue were diluted in native sample buffer, and 1 g of
protein was loaded onto a native 12% tris-glycine gel. After electropho-
resis, gels were immersed in nitroblue tetrazolium then developed with
tetramethylethylenediamine and riboflavin in KH2PO4 buffer.
Mass spectrometric quantification. The metal status and total SOD con-
centration was determined as described previously (Rhoads et al., 2011)
with the following modifications. Mouse tissues were dissected and fro-
zen on a plastic dissection plate placed on a block of dry ice to maintain a
subzero temperature. For spinal cords, 1- to 2-mm-thick transverse sec-
tions were cut with a razor blade, laid flat on the dissection plate, and
0.3-mm-diameter punches of either dorsal or ventral gray matter (300
m biopsy punch, Zivic Instruments) were obtained. The tissue was
expelled with air from the punch onto a tarred aluminum weigh boat
(VWR) and then weighed to the nearest microgram using an analytical
balance (model 25 automatic electrobalance, Cahn). Punch weights
ranged between 90 and 200 g. The punch was then mixed with 5 l of 10
mM ammonium acetate, pH 5.1, containing 500 nM bovine SOD as an
internal standard. The supernatant was then bound to an equilibrated C4
Ziptip (Millipore) and desalted by aspirating with 10 l of deionized
water, which was repeated six times. The point of the Ziptip was then
pressed into PEEK tubing, leading to the electrospray ionization source
of an LTQ-FT Ultra MS unit (Thermo Scientific) with an electrospray
ionization interface in positive-ion mode. A second piece of PEEK tubing
coming from the HPLC pump was inserted into the rear of the Ziptip,
and the tip was then perfused with a mobile phase of 30% (v/v) acetoni-
trile/water with 100 M formic acid (at 30 ml/min). The elution of SOD
occurred over 2–3 min, after which time the total ion count returned to
baseline. Integration and quantitation of SOD was performed as de-
scribed previously (Rhoads et al., 2011, 2013).
Size exclusion chromatography inductively couple plasma mass spec-
trometry. Liquid chromatography coupled to inductively coupled plasma
mass spectrometry (LC-ICPMS) was performed using an HPLC unit
(model 1200, Agilent) equipped with binary pumps, an in-line degasser,
a thermostat-controlled column compartment, a variable wavelength
detector, and a temperature controlled autosampler. The HPLC was di-
rectly connected to a Teflon Mira Mist Nebulizer with PEEK tubing. An
Agilent 7700 series ICPMS instrument was used as a multielemental
detector and was operated in He mode (4.3 ml/min) under routine mul-
tielemental operating conditions. Samples were chromatographically
separated with a BioSEC3 size exclusion column (4.6  300 mm, 300Å;
Agilent) with 200 mM ammonium nitrate, pH 8.0, at a flow rate of 0.4
ml/min (145 cm/h, 30°C). The size exclusion column was calibrated
using the following molecular weight standards, and elution volume was
monitored both by absorbance (280 nm) and by ICPMS (mass of each
standard, element detected by ICPMS, and source of standard are shown
in parentheses): thyroglobin (667 kDa; I; GE), ferritin (440 kDa; Fe; GE),
catalase (232 kDa; Fe; GE), albumin (64 kDa; Fe, Cu, Zn; GE), bovine
SOD1 (32 kDa; Cu, Zn; Sigma), and vitamin B12 (1.2 kDa; Co; Sigma),
and the integration time for each element was 0.2 s. A standard curve of
SOD1 (bovine, Sigma) was also determined by measuring the amount of
SOD protein (258  10,300 M
	1 cm 	1), and the total amount of Cu
and Zn was determined by bulk measure ICPMS. The standard curve was
linear over the range of 1–1000 pmol SOD injected on column (r 2

0.98). PBS-soluble spinal cord extracts (prepared as described above)
containing 200 g of total protein were injected on column (20 l
injections) and developed for 1.6 column volumes (8 ml).
Laser ablation inductively couple plasma mass spectrometry. Laser ablation
ICPMS (LA-ICPMS) imaging mass spectrometry was performed on
paraformaldehyde-fixed spinal cord transverse sections, as previously
described (Hare et al., 2012; Lear et al., 2012). Imaging mass spectrome-
try is a relatively new analytical science that combines discrete solid sam-
pling with mass specific detection. LA-ICPMS uses high-energy laser
pulses to provide a source of particles for inorganic mass spectrometry,
allowing spatial profiling of trace metals directly in solid samples. Quan-
titative images depicting the spatial distribution of metals in tissue sec-
tions are produced by rastering the laser beam across the tissue
surface.
Statistical analyses. The Kolmogorov–Smirnov test for normality
(with a Dallal-Wilkinson-Lilliefor-corrected p value) was applied to all
datasets to test for Gaussian distribution. Normally distributed data were
analyzed using the unpaired t test when comparing the mean of two
datasets or a two-way ANOVA (with Bonferroni post-tests). Data that
did not fit Gaussian distribution were analyzed using the Mann–Whitney
test when comparing the mean of two datasets. The statistical significance
of mouse survival data was determined using the Log-rank (Mantel–
Cox) test. The statistical significance of locomotor function data was
determined using a two-way repeated-measures ANOVA.
Results
Cu II(atsm) is protective in SOD1G37R mice
Daily treatment with CuII(atsm) improves locomotor function and
survival of SOD1G37R mice in a dose-dependent manner without
affecting locomotor function of nontransgenic littermates (McAllum
et al., 2013; Fig. 1A). The observed therapeutic outcomes involve
broad protection against the toxic effects of mutant SOD1 as treat-
ment with CuII(atsm) preserved the number of -motor neurons in
the spinal cord (Fig. 1B), decreased levels of oxidatively modified
proteins (Fig. 1C), decreased the abundance of GFAP-
immunoreactive cells (astrocytes) within spinal cord gray matter,
and decreased the abundance of activated microglia (Fig. 1D). All
biochemical and histological analyses were performed on tissues col-
lected at the mid-symptom age of 24 weeks, as indicated by the
vertical dashed line in Figure 1A. Relatively modest changes in
-motor neuron numbers are consistent with the severity of disease
symptoms at this age (Feeney et al., 2001).
Cu II(atsm) increases levels of mutant SOD1 in vivo by
increasing the Cu content of the protein
We examined whether therapeutic activity of Cu II(atsm) was re-
lated to effects on levels of mutant SOD1. Surprisingly, an in-
crease in the mutant form of SOD1 was detected in the spinal
cords of Cu II(atsm)-treated mice. This was evident via Western
blot (Fig. 2A,B) and histology (Fig. 2C). Endogenous, wild-type
mouse SOD1 was not affected by the Cu II(atsm) treatment (Fig.
2A,B). A substantial pool of metal-deficient SOD1 (i.e., where
each monomer equivalent of SOD1 contains one Cu ion or one
Zn ion, but not both) was decreased by the Cu II(atsm) treatment,
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whereas the increase in total SOD1 was
driven by an increase in the pool of fully
metallated holo-SOD1 (Fig. 2D). Conver-
sion of metal-deficient SOD1 to holo-
SOD1 appeared to be driven by the
delivery of Cu to the mutant protein as
Cu-deficient SOD1 was the only form of
metal-deficient SOD1 that decreased (Fig.
2E), as indicated by the strong correlation
between metal-deficient SOD1 and Cu-
deficient SOD1 (Fig. 2F). There was no
correlation between metal-deficient SOD1
and Zn-deficient SOD1 (R 2  0.003, p 
0.8; data not shown). Supporting an in-
crease in the amount of SOD1 that con-
tained Cu, SOD activity was increased in
the spinal cords of Cu II(atsm)-treated
SOD1G37R mice (Fig. 2G).
LA-ICPMS data (Fig. 3) showed that
oral treatment with Cu II(atsm) increased
the Cu content of the spinal cords of non-
transgenic mice 2.2-fold (Fig. 3), and this
is consistent with data showing that orally
administered Cu II(atsm) penetrates CNS
tissue (Soon et al., 2011; Hung et al.,
2012). The increase in spinal cord Cu was
more pronounced in SOD1G37R mice
(Fig. 3B), indicating that the Cu II(atsm)
had elevated penetration of CNS tissue in
SOD1G37R mice or that the compound
was selectively retained and/or metabo-
lized within the CNS tissue of SOD1G37R
mice. Treatment with Cu II(atsm) also in-
creased the overall levels of Zn in spinal
cords of SOD1G37R mice, but, unlike Cu,
the increase in Zn was not evident in non-
transgenic mice (Fig. 3). Fe levels (Fig. 3)
and Mn levels (data not shown) were not
changed.
To gain further information on the
Cu II(atsm)-induced changes within the
pool of holo-SOD1G37R and its associ-
ated metal ions Cu and Zn, we performed
size exclusion LC-ICPMS. This metallo-
proteomic approach revealed that Cu and
Zn were both increased in SOD1 by the
Cu II(atsm) treatment (Fig. 4A,B). The
Cu/Zn ratio within the SOD1G37R cal-
culated from these LC-ICPMS data con-
Figure 2. Effects of Cu II(atsm) on SOD1G37R in the spinal cord tissue of SOD1G37R mice. A, Representative Western blot images
showing the effects of Cu II(atsm) on levels of SOD1G37R in the spinal cords of SOD1G37R mice, and on the levels of endogenous
wild-type SOD1 (SOD1WT) in nontransgenic littermates. Levels of GAP43 are shown as a loading control. B, Densitometry analysis
of Western blot analyses represented in A. C, Representative histology images for human SOD1 immunoreactivity in spinal cord
transverse sections from SOD1G37R mice and nontransgenic littermates. D, Mutant SOD1 in the spinal cords of SOD1G37R mice
determined by mass spectrometry showing concentrations of apo, metal-deficient, and holo forms of the protein as well as the
total concentration of the protein. E, Concentration of zinc-deficient and copper-deficient forms of the metal-deficient pool of
4
mutant SOD1. Note the same scale on the y-axes in D and E. F,
Correlation between levels of metal-deficient SOD1 (from D)
and copper-deficient SOD1 (from E) in the spinal cords of
sham-treated and Cu II(atsm)-treated SOD1G37R mice. There
was no correlation between metal-deficient SOD1 and zinc-
deficient SOD1 (R 2  0.003, p  0.8; data not shown). G,
Activity of SOD in spinal cord samples expressed relative to
sham-treated, nontransgenic littermate controls. Asterisks in-
dicate the statistical significance relative to sham-treated
SOD1G37R mice or as otherwise indicated: *p  0.05, **p 
0.01. n  5– 8 for all treatment groups in A, B, and G; n 
10 –11 in D–F; n  4 in C. Error bars represent the SEM.
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firmed that SOD1G37R in the spinal cords of vehicle-treated
mice was relatively Cu deficient (Fig. 4C). The Cu II(atsm)-
induced increase in the SOD1G37R Cu/Zn ratio was consis-
tent with the LA-ICPMS data (Fig. 3), which showed that
Cu II(atsm) had a greater effect on Cu levels in the spinal cord
compared with Zn.
Data in Figures 3 and 4 collectively indicate that treatment
with Cu II(atsm) increases the total levels of Cu and Zn and the
amount of holo-mutant SOD1 within the spinal cord tissue. Cu II-
(atsm) has the capacity to increase levels of bioavailable Cu and
Zn in cells in vitro (Donnelly et al., 2012). This indicates that the
increase in Cu in the mutant SOD1 (Fig. 4A) involved the transfer
of Cu from Cu II(atsm) to SOD1, and that the increase in Zn
occurs via an indirect mechanism. To probe further the in vivo
transfer of Cu from Cu II(atsm) to mutant SOD1, mice were
treated with Cu II(atsm) isotopically enriched with 65Cu. This
naturally occurring isotope is less abundant than the predomi-
nant 63Cu isotope, with the natural ratio of 0.45:1 ( 65Cu/ 63Cu).
LC-ICPMS analysis of spinal cord tissue demonstrated an in-
crease in abundance of 65Cu in the SOD1 of 65Cu II(atsm)-treated
mice (Fig. 4D), indicating a transfer of Cu from Cu II(atsm) to the
SOD1. Based on a total spinal cord wet weight of 50 mg, the
data in Figure 4D equate to 2% of the total Cu delivered orally
to the mice as Cu II(atsm) was being transferred to SOD1 in the
spinal cord.
Figure 3. Metal content of spinal cord tissue from SOD1G37R mice and nontransgenic litter-
mates. A, Representative reconstructed images of LA-ICPMS data showing amounts of Cu, Zn,
and Fe in spinal cord transverse sections. The pixel color represents metal ion abundance, as
indicated by the spectra shown for each metal ion. B, Mean data collected from LA-ICPMS
analyses, as represented in A. Mean data are for whole spinal cord transverse sections and
therefore include apparent regionalized differences in signal intensity. Asterisks indicate statis-
tical significance, as indicated: *p  0.05, **p  0.01. n  4 for all treatment groups. Error
bars represent the SEM.
Figure 4. Effects of Cu II(atsm) on the metal content of SOD1 in spinal cords of SOD1G37R
mice. A, Mean LC-ICPMS traces showing the effects of Cu II(atsm) on Cu content of SOD1 in spinal
cords of SOD1G37R mice. B, Mean LC-ICPMS traces showing the effects of Cu II(atsm) on the Zn
content of SOD1 in spinal cords of SOD1G37R mice. SOD1 eluted at 3.4 ml is indicated by a
vertical arrow in A and B. C, Mean data derived from SOD1 peak in A and B, showing the effects
of Cu II(atsm) on the molar Cu/Zn ratio in SOD1 from the spinal cords of SOD1G37R mice. The
Cu/Zn ratio in purified bovine SOD1 is shown as a control. D, Molar 65Cu/ 63Cu ratio in SOD1 from
the spinal cords of sham-, Cu II(atsm)-, and 65Cu II(atsm)-treated SOD1G37R mice determined
by LC-ICPMS, as in A and B. The horizontal red dashed line shows the natural isotopic distribu-
tion of the 65Cu/ 63Cu ratio in biological material (0.45:1). Values above this line indicate an
increase in the relative amount of 65Cu in the SOD1. Asterisks indicate the statistical significance
(**p  0.01). n  6 –7 for all treatment groups, except for the bovine SOD1 standard in C,
where n  4. Symbols in D represent data for individual mice. Error bars represent the SEM.
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Treatment with Cu II(atsm) did not decrease levels of
misfolded SOD1
Suboptimal metal content of SOD1 can promote SOD1 misfold-
ing and aggregation (Lynch et al., 2004; Rumfeldt et al., 2009; Ip
et al., 2011), and misfolded and aggregated SOD1 is a consistent
feature of ALS (Bruijn et al., 1998; Furukawa et al., 2006; Wang et
al., 2008; Chattopadhyay and Valentine, 2009; Prudencio et al.,
2009), including sporadic ALS (Bosco et al., 2010). Given that
Cu II(atsm) improved the metal content of the mutant SOD1
(Fig. 3), the levels of misfolded SOD1 in the spinal cords of
Cu II(atsm)-treated SOD1G37R mice were assessed using three
antibodies raised against misfolded SOD1 (Bosco et al., 2010;
Gros-Louis et al., 2010). Misfolded SOD1 was readily detectable
in the soluble fraction of spinal cords from SOD1G37R mice, but
the Cu II(atsm) treatment did not significantly alter its abundance
(Fig. 5A–C). The results for all three antibodies trended toward
an increase in misfolded SOD1 in the soluble fraction in the
Cu II(atsm)-treated mice, and this was supported by histology
data (Fig. 5D). Consistent with previous reports (Rakhit et al.,
2007; Zetterström et al., 2007; Brotherton et al., 2012), levels of
misfolded SOD1 were low or nondetectable in the insoluble frac-
tion (Fig. 5A–C).
Increasing spinal cord Cu via the Cu
uptake transporter CTR1 improved the
survival of SOD1G37R mice
To help assess the significance of Cu deliv-
ery in the protective activity of Cu II(atsm)
in SOD1G37R mice, we aimed to increase
spinal cord Cu levels via an alternate
method. This was achieved by crossing
SOD1G37R mice with mice that express
the gene for the human Cu uptake trans-
porter CTR1. The expression of hCTR1 in
the spinal cord tissue (Fig. 6A) induced a
19% increase in spinal cord Cu levels
without altering levels of Zn or Fe (Fig.
6B). Expression of endogenous mCtr1 was
not altered by the expression of hCTR1
(Fig. 6A). The elevation in spinal cord Cu
levels translated into a modest (but statis-
tically insignificant) improvement in lo-
comotor function (Fig. 6C) and a
significant (p  0.006) 12% increase in
the median survival time of SOD1G37R
mice (Fig. 6D).
Discussion
Early studies showed that higher levels of
expressed mutant SOD1 correlate with
more rapid onset and progression of dis-
ease symptoms in the ALS model mice
(Gurney et al., 1994; Wong et al., 1995;
Dal Canto and Gurney, 1997). This corre-
lation is substantiated by delayed symp-
toms in ALS mice due to decreased
mutant SOD1 levels (Ralph et al., 2005;
Urushitani et al., 2007; Henriques et al.,
2010). Because of this clear apparent rela-
tionship between mutant SOD1 levels and
the phenotype of the mice, we measured
SOD1 in the spinal cords of Cu II(atsm)-
treated SOD1G37R mice. Despite the fact
that Cu II(atsm) treatment improved
mouse locomotor function and survival
(McAllum et al., 2013; Fig. 1A), we found that it significantly
increased the mutant protein in vivo (Fig. 2), thereby disproving
the assertion that the phenotype of mutant SOD1 mice is propor-
tional to levels of the mutant protein.
Mass spectrometry analyses indicated that Cu II(atsm) pro-
moted conversion of metal-deficient SOD1 to holo-SOD1 (Fig.
2D–F) via in vivo transfer of Cu from Cu II(atsm) to the mutant
SOD1; the Cu content of SOD1 was increased (Fig. 4A) and 65Cu
from orally administered 65Cu II(atsm) was recovered in spinal
cord SOD1 (Fig. 4D). These outcomes are consistent with the
high stability of holo-SOD1 (Forman and Fridovich, 1973), re-
gardless of the presence of ALS-associated mutations (Banci et al.,
2007), and support the findings of in vitro studies that indicate
SOD1 toxicity can be prevented by improving the metallation
state of the protein (Estévez et al., 1999). These outcomes indicate
that the metal content of SOD1 may be a greater determinant of
the toxicity of the protein in mutant SOD1-associated forms of
ALS than the mutations themselves.
A number of mechanisms have been proposed to explain how
an altered metal content of SOD1 may cause ALS. One of these
involves pro-oxidant gain of function for Zn-deficient SOD1
Figure 5. Misfolded SOD1 in spinal cords of SOD1G37R mice. A–C, Levels of misfolded mutant SOD1 in PBS-soluble and
PBS-insoluble fractions of SOD1G37R mouse spinal cords detected using native PAGE and the B8H10 (A), A5C3 (B), and C4F6 (C)
antibodies. Values are derived from densitometry analysis of Western images (representative images shown) and are expressed
relative to the immunoreactivity detected in the soluble fraction of sham-treated mice. N.D., nondetectable levels in the insoluble
fraction using these antibodies. D, Representative histology images for misfolded SOD1 immunoreactivity in spinal cord transverse
sections using the B8H10 antibody (top row) and the C4F6 antibody (bottom row). Immunoreactivity using the A5C3 antibody was
not detected by histology (data not shown). E, Immunoreactivity for the three antibodies was not detected in nontransgenic mice,
indicating specificity for the human mutant form of the protein. n  4 –5 for all treatment groups. Error bars in A–C represent the
SEM.
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(Crow et al., 1997). This proposed toxic
gain of function requires the retention of
Cu in Zn-deficient SOD1, as it is the redox
activity of Cu that catalyzes the produc-
tion of reactive oxygen and nitrogen spe-
cies (Crow et al., 1997; Estévez et al., 1999;
Sahawneh et al., 2010). This toxic mecha-
nism of action is supported by a number
of lines of evidence (Estévez et al., 1999;
Roberts et al., 2007; Sahawneh et al.,
2010), and although the Zn-deficient pool
of SOD1 accounts for only 1% of SOD1
in the SOD1G37R (Fig. 2E), our data
show that the concentration of Zn-
deficient SOD1 in spinal cord tissue is
higher than concentrations that induce
motor neuron toxicity in vitro (Sahawneh
et al., 2010). However, SOD1 mice in
which all four Cu-coordinating histidine
residues in the mutant SOD1 are removed
have been developed, and these mice still
develop ALS-like symptoms (Wang et al.,
2003). While the phenotype of these
“quad mutant” mice does not exclude the
Cu-mediated SOD1 toxicity occurring via
Cu that binds to the SOD1 Zn-binding
site (Valentine et al., 1979), the absence of
any significant changes to the pool of Zn-
deficient SOD1 in Cu II(atsm)-treated
SOD1G37R mice indicates that the mod-
ulation of Zn-deficient SOD1 is not part
of the therapeutic mechanism of action
for Cu II(atsm).
Metal-free (apo) SOD1 readily misfolds
and aggregates (Arnesano et al., 2004; Lynch
et al., 2004; Furukawa et al., 2008; Durazo et
al., 2009; Rumfeldt et al., 2009; Tiwari et al.,
2009), thus potentially giving rise to the
SOD1 aggregates present in some forms of
ALS. Significantly, ALS-causing SOD1
mutations promote SOD1 misfolding via
a pathway in which the mutant SOD1
preferentially loses Cu (Ip et al., 2011),
and restoration of the full metal compli-
ment of the protein makes it relatively in-
distinguishable from holo wild-type
SOD1 (Banci et al., 2007). However, de-
spite this relationship between Cu defi-
ciency and SOD1 misfolding, preventing
the formation of misfolded SOD1 is not
the mechanism through which Cu II-
(atsm) improved the locomotor function
and survival of SOD1G37R mice, as none
of the antibodies used to assess the levels
of misfolded SOD1 revealed a decrease in
the pool of misfolded SOD1 (Fig. 5A–D).
In fact, all three antibodies indicated that the soluble pool of
misfolded SOD1 increased in equilibrium with the total pool of
SOD1 (Fig. 2A). Previous studies have shown that decreasing the
levels of misfolded SOD1 improves the survival and locomotor
function of mutant SOD1 mice, suppresses inflammatory re-
sponses, and protects spinal cord motor neurons (Gros-Louis et
al., 2010; Liu et al., 2012), outcomes that were all detected in
Cu II(atsm)-treated SOD1G37R mice (Fig. 1). Without preclud-
ing the potential contribution of methodological differences be-
tween the studies, these apparent disparate outcomes may
indicate that SOD1-mediated dysfunction in ALS is not due to a
single toxic species of SOD1, and that misfolded SOD1 contrib-
utes only partially to the decreased neuron functionality in ALS.
Supporting this, none of the therapeutic interventions tested to
Figure 6. Effects of expressed hCTR1 on the locomotor function and survival of SOD1G37R mice. A, Levels of mRNA for hCTR1 and
mCtr1 in the spinal cords of hCTR1 mice and nontransgenic (non-Tg) littermates. hCTR1 levels are expressed relative to levels of the
endogenous mCtr1, and levels of mCtr1 are expressed relative to levels of endogenous mActb. B, Copper, zinc, and iron content of
spinal cord tissue from mice expressing hCTR1 compared with nontransgenic littermates, as determined using LA-ICPMS as in
Figure 3. n  6 for both genotypes in A and B. C, Locomotor function of SOD1G37R and hCTR1xSOD1G37R mice measured as the
latency to fall on the rotarod assay (n  14 SOD1G37R mice, n  8 hCTR1xSOD1G37R mice). D, Fraction of SOD1G37R and
hCTR1xSOD1G37R mice alive relative to age (n  24 SOD1G37R mice, n  8 hCTR1xSOD1G37R mice). Regardless of genotype,
mice were culled when complete paralysis was present in at least one hindlimb and were unable to right themselves within 15 s
after being laid down on their side. Asterisks indicate the statistical significance (*p  0.05). Error bars represent the SEM.
Figure 7. Schematic to indicate how both chelation and supplementation therapeutic strategies can attenuate SOD1 toxicity.
Apo- and holo-SOD1 are nontoxic; apo-SOD1 is rapidly turned over, whereas holo-SOD1 is the stable, functional antioxidant form.
Toxicity of the labile, metal-deficient intermediate can be prevented by chelating agents that convert holo-SOD1 to apo-SOD1, or
by agents such as Cu II(atsm), which convert apo-SOD1 to holo-SOD1.
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date, including Cu II(atsm), has completely prevented death or
locomotor deficits in ALS model mice.
SOD1 that is relatively Cu deficient and Zn replete has been
reported in the spinal cords of ALS model mice (Lelie et al., 2011)
and is supported by data shown in Figure 4C. Our observation
that Cu-deficient SOD1 was the only pool of SOD1 decreased by
Cu II(atsm) indicates that if the phenotype of the SOD1G37R
mice is driven solely by mutant SOD1, increasing bioavailable Cu
in the spinal cord is beneficial because it decreases the abundance
of the Cu-deficient pool of SOD1. This is supported by data
showing that the overexpression of CTR1 improves the survival
of SOD1G37R mice (Fig. 6), and by data showing that Cu admin-
istered orally as Cu II(atsm) is recovered in spinal cord SOD1 (Fig.
4D). However, modulating the levels of spinal cord Cu to treat
mutant SOD1 mice has been investigated previously, and the out-
comes often indicate that decreasing Cu is beneficial. Treatment
with ammonium tetrathiomolybdate, for example, is effective in
mutant SOD1 mice via a mechanism proposed to involve attenua-
tion of the Cu dyshomeostasis caused by mutant SOD1, and is sup-
ported by data that show the treatment decreases the levels of spinal
cord Cu and removes Cu from the SOD1 active site (Tokuda et al.,
2008, 2013). Conversely, treating mutant SOD1 rats with pyrroli-
dine dithiocarbamate, a compound capable of increasing Cu levels
in CNS tissue (Malm et al., 2007), accelerated the ALS-like pheno-
type of mutant SOD1 rats (Ahtoniemi et al., 2007). Targeting metal
ion homeostasis, therefore, has good in vivo support as a strategy for
treating ALS, but the interpretation of outcomes from studies that
use notional metal-chelating agents, as opposed to metal delivery
agents, is complicated by an incomplete understanding of the activ-
ity of these compounds at the cellular level, as was recently reviewed
(Crouch and Barnham, 2012).
Other studies have attempted to modulate disease symptoms
in mutant SOD1 mice by genetic modification of Cu transporters
and chaperones. The first of these studies used mice that had no
Cu chaperone for SOD1 (CCS), a cellular chaperone that delivers
intracellular Cu to SOD1. The SOD1/CCS	/	 mice had de-
creased Cu levels in SOD1 but did not have an altered phenotype,
thus generating the conclusion that the Cu content of mutant
SOD1 did not contribute to SOD1 toxicity in vivo (Subramaniam
et al., 2002). This interpretation has been criticized (Beckman et
al., 2002; Kiaei et al., 2004) based on data that show CCS is not the
only chaperone that delivers Cu to SOD1 (Carroll et al., 2004). By
contrast, mice that express mutant SOD1 and a dysfunctional
Cu-transporting ATPase 1 (ATP7A) displayed increased survival
and locomotor function relative to mutant SOD1 mice with func-
tional ATP7A, and it was shown that the expression of the dys-
functional ATP7A significantly decreased global levels of spinal
cord Cu (Kiaei et al., 2004). Also, the overexpression of CCS in
mutant SOD1 mice dramatically accelerates disease onset and
premature death (Son et al., 2007). Data from the CTR1-
overexpressing mice (Fig. 6) support the outcomes from our
Cu II(atsm) studies, but on face value appear to oppose outcomes
from mice with altered CCS or ATP7A functionality. Fundamen-
tal differences between the Cu transporters and chaperones mod-
ulated in these studies and their likely differing effects with
respect to metallo-proteins other than SOD1 will have contrib-
uted to these apparent opposing outcomes. If anything, these
studies demonstrate the often underestimated complexity of bio-
metal metabolism. More information on how the metal content
of SOD1 and other cupro-proteins is changed in these models is
needed to reconcile these disparate outcomes.
While the definitive roles for altered Cu and Zn homeostasis
in the toxic gain of function of SOD1 continue to be debated, the
suboptimal metal content of SOD1 is nonetheless emerging as an
important factor with excellent potential for therapeutic inter-
vention. Our data indicate that Cu II(atsm) may mediate its pro-
tective effects, at least in part, by delivering Cu to Cu-deficient
SOD1, thereby converting it to stable, nontoxic holo-SOD1. This
therapeutic strategy does not preclude the potential benefits of
removing Cu from, for example, Zn-deficient SOD1 to prevent a
pro-oxidant gain of function. When considered with outcomes
from previous studies, our data support the conclusion that at
least part of the toxic gain of function of SOD1 resides in a metal-
deficient intermediate, and that driving the protein toward holo-
SOD1 via metal delivery or toward apo-SOD1 via sequestration
appears to have comparable therapeutic potential (Fig. 7). Our
data add support to the strengthening hypothesis that combina-
tion therapy is likely to provide the best outcomes for patients
with ALS.
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